Bicara Therapeutics

Q2 FY2026 EarningsQ2 FY26 results for BCAX were mixed compared to consensus, with a narrower-than-expected net loss but slightly higher-than-anticipated operating losses. GAAP EPS of -$0.82 beat the -$0.84 consensus, while total net loss of $55.4M was better than the $53.7M expected loss. The company reported zero revenue as expected for its clinical stage, but R&D and G&A scaling drove a total operating loss of $60.0M, missing the $57.9M consensus. A strategic leadership transition was announced alongside a robust cash position of $497.3M, extending the runway into 1H 2029.